Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 14Uterine Cervical Neoplasms 6Carcinoma, Ovarian Epithelial 6Stomach Neoplasms 5Fallopian Tube Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasms 4Endometrial Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Vaginal Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Peritoneal Neoplasms 2Melanoma 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Vulvar Neoplasms 1Urethral Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Penile Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Multiple Myeloma 1

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2toripalimab 1sintilimab 1camrelizumab 1anlotinib 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cervical Cancer × Capecitabine × Gynecologic × Clear all
NCT04508686 2021-01-29

Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)

Ruijin Hospital

Phase 1 Unknown
20 enrolled
Gynecologic

Advanced Cervical Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡